Recent Updates
Recently added Catalysts
SNDX Positive Sentiment

Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update

Tuesday, August 4, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Syndax reported a strong financial performance for the second quarter of 2026, with total revenues reaching $73 million, marking a 92% increase compared to the previous year. The company's Revuforj® (revumenib) generated net revenues of $54.7 million, while Niktimvo™ (axatilimab-csfr) achieved net revenues of $60.3 million, reflecting significant year-over-year growth.

Market Sentiment Analysis

POSITIVE FACTORS

  • Total revenue increased by 92% year-over-year.
  • Revuforj® (revumenib) net revenue rose by 91%.
  • Niktimvo™ (axatilimab-csfr) net revenue increased by 67%.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+133%
120-day peak, hindsight
Typical move
4.6%
average across 6 past catalysts
Cash runway
~41 mo
Low dilution risk
Lead asset
entinostat
Phase 1 · Epithelial Ovarian Cancer

Full Press Release Details

– Total revenue of $73 million in 2Q26, a 92% year-over-year increase – – Revuforj ® (revumenib) net revenue of $54.7 million in 2Q26, a 91% year-over-year increase – – Niktimvo™ (axatilimab-csfr) net revenue of $60.3 million in 2Q26, a 67% year-over-year increase, resulting in Syndax collaboration

Frequently Asked Questions

What was Syndax's total revenue in Q2 2026?

Syndax reported a total revenue of $73 million in Q2 2026.

How much did Revuforj® earn in Q2 2026?

Revuforj® (revumenib) generated net revenue of $54.7 million.

What was the year-over-year growth for Niktimvo™?

Niktimvo™ (axatilimab-csfr) saw a 67% year-over-year increase in revenue.

What is the significance of Syndax's Q2 2026 results?

The results reflect a strong financial performance with significant revenue growth.

ShareAdd on Google
Tags: SNDX Viatris Investor Conferences Healthcare Revuforj Niktimvo financial results biopharma
Last updated: Aug 4, 2026

Biotech snapshot

Cash runway
$548M liquidity · $13M/mo burn
~41 mo
Low dilution risk
Lead asset
entinostatPhase 1
Epithelial Ovarian Cancer →

Catalyst track record

+133%
best trade around SNDX's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for SNDX.

See every catalyst's timing & PoA →